PHARMADVICE ApS Financials, key figures and credit report
Gross profit 6 375.7 kDKK FY 2025 -5.1% vs 2024
EBIT 662.4 kDKK FY 2025 -22.9% vs 2024
Net debt - 216.5 kDKK FY 2025 +60.6% vs 2024
Quick ratio 2.7 FY 2025 -0.4 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 3 927.62 | 5 311.83 | 5 940.07 | 6 719.18 | 6 375.69 |
| Employee benefit expenses | -3 547.27 | -4 365.41 | -5 132.41 | -5 860.01 | -5 707.43 |
| Total depreciation | -14.80 | -15.12 | -12.27 | -0.34 | -5.85 |
| EBIT | 365.55 | 931.29 | 795.38 | 858.83 | 662.42 |
| Other financial income | 0.20 | 8.62 | 9.45 | ||
| Other financial expenses | -10.99 | -10.43 | -15.33 | -22.44 | -26.01 |
| Pre-tax profit | 354.56 | 920.87 | 780.25 | 845.01 | 645.86 |
| Income taxes | -78.64 | - 203.87 | - 171.73 | - 186.07 | - 142.35 |
| Net earnings | 275.92 | 717.00 | 608.52 | 658.94 | 503.51 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 27.74 | 12.62 | 0.34 | 26.05 | |
| Tangible assets total | 27.74 | 12.62 | 0.34 | 26.05 | |
| Investments total | 137.70 | 153.00 | 155.00 | 158.34 | |
| Non-current other receivables | 133.18 | ||||
| Long term receivables total | 133.18 | ||||
| Inventories total | |||||
| Current trade debtors | 801.94 | 1 455.54 | 1 406.59 | 1 228.26 | 1 634.76 |
| Current amounts owed by group member comp. | 197.09 | 75.51 | |||
| Prepayments and accrued income | 18.73 | ||||
| Current other receivables | 2.31 | 31.84 | |||
| Current deferred tax assets | 68.00 | 6.17 | 6.63 | 5.03 | 3.30 |
| Short term receivables total | 872.25 | 1 512.27 | 1 413.22 | 1 430.38 | 1 713.57 |
| Cash and bank deposits | 591.83 | 622.18 | 675.20 | 549.93 | 216.51 |
| Cash and cash equivalents | 591.83 | 622.18 | 675.20 | 549.93 | 216.51 |
| Balance sheet total (assets) | 1 625.00 | 2 284.77 | 2 241.76 | 2 135.32 | 2 114.48 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 125.00 | 125.00 | 125.00 | 125.00 | 125.00 |
| Shares repurchased | 25.00 | 700.00 | 600.00 | 600.00 | 400.00 |
| Retained earnings | 413.37 | -10.70 | 106.30 | 114.82 | 373.76 |
| Profit of the financial year | 275.92 | 717.00 | 608.52 | 658.94 | 503.51 |
| Shareholders equity total | 839.30 | 1 531.30 | 1 439.82 | 1 498.76 | 1 402.27 |
| Non-current liabilities total | |||||
| Current trade creditors | 70.51 | 221.82 | 165.33 | 186.74 | 190.24 |
| Current owed to group member | 17.26 | ||||
| Short-term deferred tax liabilities | 210.70 | 287.28 | 172.19 | 184.47 | 140.62 |
| Other non-interest bearing current liabilities | 354.99 | 244.37 | 447.16 | 265.36 | 381.34 |
| Accruals and deferred income | 149.51 | ||||
| Current liabilities total | 785.71 | 753.47 | 801.94 | 636.57 | 712.21 |
| Balance sheet total (liabilities) | 1 625.00 | 2 284.77 | 2 241.76 | 2 135.32 | 2 114.48 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated